Latest Amicus Therapeutics (FOLD) Headlines
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Tuesday
Amicus Therapeutics Announces Full-Year 2013 Financial Results and Corporate Updates
GlobeNewswire - Mon Mar 03, 3:01PM CST
Executing 3-in-3 Strategy to Advance 3 Next-Generation ERTs into Clinic in Next 3 Years
Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and Promotes Bradley L. Campbell to Chief Operating Officer
GlobeNewswire - Mon Mar 03, 6:30AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the appointment of Jay A. Barth, MD as Chief Medical Officer, effective today. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. In his role as Chief Medical Officer, he will be responsible for all clinical development activities as well as regulatory affairs. The Company also announced the promotion of Bradley L. Campbell from Chief Business Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
Amicus Therapeutics to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Thu Feb 27, 9:12AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014 at 10:00 a.m. ET.
Amicus Therapeutics, Inc. [FOLD] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Thu Feb 27, 9:00AM CST
What:
Amicus Therapeutics to Announce Full-Year 2013 Financial Results on March 3, 2014
GlobeNewswire - Wed Feb 26, 8:51AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, March 3, 2014 at 5:00 p.m. ET to discuss financial results for the full year ended December 31, 2013.
Amicus Therapeutics Highlights Data Featured at Lysosomal Disease Network WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
First Scientific Meeting to Present Preclinical Proof-of-Concept Data for Next-Generation Pompe ERT and Proprietary Enzyme Targeting Technology
Amicus Therapeutics to Present at 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 11, 9:01AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that William D. "Chip" Baird, Chief Financial Officer and Bradley L. Campbell, Chief Operating Officer, will participate in a presentation and fireside chat at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:25 p.m. ET.
Gaucher's Disease - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/88zfnr/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2013" report to their offering. 'Gaucher's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gaucher's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher's Disease. Scope - A snapshot of the global therapeutic scenario for Gaucher's Disease. - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Gaucher's Disease Overview Therapeutics Development Pipeline Products for Gaucher's Disease - Overview Pipeline Products for Gaucher's Disease - Comparative Analysis Gaucher's Disease - Therapeutics under Development by Companies Gaucher's Disease - Therapeutics under Investigation by Universities/Institutes Gaucher's Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Gaucher's Disease - Products under Development by Companies Gaucher's Disease - Products under Investigation by Universities/Institutes Gaucher's Disease - Companies Involved in Therapeutics Development Gaucher's Disease - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles eliglustat tartrate - Drug Profile acetylcysteine - Drug Profile ambroxol - Drug Profile PRX-112 - Drug Profile AT-3375 - Drug Profile JR-101 - Drug Profile NP-003 - Drug Profile imiglucerase Biosimilar - Drug Profile LB-201 - Drug Profile LB-205 - Drug Profile Gluco-Cerebosidase - Drug Profile BNT-001 - Drug Profile Glucocerebrosidase Activators - Drug Profile DOS-000011 - Drug Profile imiglucerase Biosimilar - Drug Profile Companies Mentioned Genzyme Corporation Amicus Therapeutics, Inc. Lixte Biotechnology Holdings, Inc. Protalix BioTherapeutics, Inc. JCR Pharmaceuticals Co., Ltd. greenovation Biotech GmbH Neuraltus Pharmaceuticals, Inc. Biosidus S.A. ExSAR Corporation Bioorganic Research and Services S.A. Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/88...rs_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Court Orders Martha Stewart, Emeril Lagasse, Home Shopping Network to Stop Using "SOLINGEN" Certification Mark
Marketwire - Tue Feb 04, 9:17AM CST
Attorneys with Mayback & Hoffman and Devine Goodman, et al. announced that a Tampa federal judge has issued a permanent injunction prohibiting Martha Stewart, Emeril Lagasse, and their respective companies; the Home Shopping Network; and SED International Holdings Inc. from using the "SOLINGEN" certification mark.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013 Report
M2 - Mon Feb 03, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f28drr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013" report to their offering. 'Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Scope - A snapshot of the global therapeutic scenario for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - A review of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Athersys, Inc. OPKO Health, Inc. Amicus Therapeutics, Inc. ReGenX Biosciences, LLC ArmaGen Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/f2...saccharido About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium
GlobeNewswire - Thu Jan 30, 3:01PM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that three oral presentations and five posters highlighting its development programs for lysosomal storage diseases will be included at the 10 Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 10-14, 2014 in San Diego, CA.
BioNJ to Honor Patient Advocacy Leaders at Annual Meeting Thursday
Business Wire - Wed Jan 29, 1:12PM CST
BioNJ will honor the first recipients of its Patient Advocate Award tomorrow evening at the BioNJ 21st Annual Dinner Meeting and Networking Event, recognizing outstanding leadership efforts to represent patient interests in the biotechnology and pharmaceutical industries, scientific research and public arenas.
Pompe Disease - Pipeline Review, H2 2013
M2 - Fri Jan 24, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjm87q/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pompe Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pompe Disease. Pompe Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Pompe Disease. - A review of the Pompe Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pompe Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Pompe Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pompe Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and underst Companies Mentioned - Amicus Therapeutics - Audentes Therapeutics - BioMarin Pharmaceutical - EpiVax - Genzyme Corporation - Oxyrane Belgium - Valerion Therapeutics For more information visit http://www.researchandmarkets.com/research/cj...pe_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Amicus Therapeutics Up 9.6%, Shares Break Through Resistance (FOLD)
Comtex SmarTrend(R) - Tue Jan 21, 11:43AM CST
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 9.6% to $2.98 on 1.2x average daily volume. Amicus Therapeutics has traded 395,000 shares thus far today, vs. average volume of 328,000 shares per day. The stock has outperformed the Dow (9.6% to the Dow's -0.6%) and outperformed the S&P 500 (9.6% to the S&P's -0.1%) during today's trading.
Amicus Therapeutics (FOLD) Soars: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:18AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by roughly 11% on the day.
Positive News for Keryx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 3:40PM CST
Positive news flowed in for Keryx Biopharmaceuticals when its Japanese partner, Japan Tobacco Inc. (JT), received manufacturing and marketing approval of Zerenex from the Japanese Ministry of Health, Labour and Welfare.
Amicus Update on Strategy, Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 4:49PM CST
Amicus Therapeutics participated in the 32nd annual J.P. Morgan Healthcare Conference.
Stock to Watch: Amicus Therapeutics Up 8.4% (FOLD)
Comtex SmarTrend(R) - Fri Jan 17, 11:41AM CST
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 8.4% to $2.67 on 2.0x average daily volume. Thus far today, Amicus Therapeutics has traded 653,000 shares, vs. average volume of 329,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's 0.4%) and outperformed the S&P 500 (8.4% to the S&P's -0.0%) during today's trading.
Amicus Therapeutics Provides Full-Year 2014 Strategic Outlook and Financial Guidance
GlobeNewswire - Mon Jan 13, 6:30AM CST
3 Next-Generation Enzyme Replacement Therapies (ERTs) Expected to Enter Clinic in Next 3 Years, Beginning in 2014
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Tuesday
Amicus Therapeutics Announces Full-Year 2013 Financial Results and Corporate Updates
GlobeNewswire - Mon Mar 03, 3:01PM CST
Executing 3-in-3 Strategy to Advance 3 Next-Generation ERTs into Clinic in Next 3 Years
Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and Promotes Bradley L. Campbell to Chief Operating Officer
GlobeNewswire - Mon Mar 03, 6:30AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the appointment of Jay A. Barth, MD as Chief Medical Officer, effective today. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. In his role as Chief Medical Officer, he will be responsible for all clinical development activities as well as regulatory affairs. The Company also announced the promotion of Bradley L. Campbell from Chief Business Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
Amicus Therapeutics to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Thu Feb 27, 9:12AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014 at 10:00 a.m. ET.
Amicus Therapeutics, Inc. [FOLD] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Thu Feb 27, 9:00AM CST
What:
Amicus Therapeutics to Announce Full-Year 2013 Financial Results on March 3, 2014
GlobeNewswire - Wed Feb 26, 8:51AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, March 3, 2014 at 5:00 p.m. ET to discuss financial results for the full year ended December 31, 2013.
Amicus Therapeutics Highlights Data Featured at Lysosomal Disease Network WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
First Scientific Meeting to Present Preclinical Proof-of-Concept Data for Next-Generation Pompe ERT and Proprietary Enzyme Targeting Technology
Amicus Therapeutics to Present at 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 11, 9:01AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that William D. "Chip" Baird, Chief Financial Officer and Bradley L. Campbell, Chief Operating Officer, will participate in a presentation and fireside chat at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:25 p.m. ET.
Gaucher's Disease - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/88zfnr/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2013" report to their offering. 'Gaucher's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gaucher's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher's Disease. Scope - A snapshot of the global therapeutic scenario for Gaucher's Disease. - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Gaucher's Disease Overview Therapeutics Development Pipeline Products for Gaucher's Disease - Overview Pipeline Products for Gaucher's Disease - Comparative Analysis Gaucher's Disease - Therapeutics under Development by Companies Gaucher's Disease - Therapeutics under Investigation by Universities/Institutes Gaucher's Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Gaucher's Disease - Products under Development by Companies Gaucher's Disease - Products under Investigation by Universities/Institutes Gaucher's Disease - Companies Involved in Therapeutics Development Gaucher's Disease - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles eliglustat tartrate - Drug Profile acetylcysteine - Drug Profile ambroxol - Drug Profile PRX-112 - Drug Profile AT-3375 - Drug Profile JR-101 - Drug Profile NP-003 - Drug Profile imiglucerase Biosimilar - Drug Profile LB-201 - Drug Profile LB-205 - Drug Profile Gluco-Cerebosidase - Drug Profile BNT-001 - Drug Profile Glucocerebrosidase Activators - Drug Profile DOS-000011 - Drug Profile imiglucerase Biosimilar - Drug Profile Companies Mentioned Genzyme Corporation Amicus Therapeutics, Inc. Lixte Biotechnology Holdings, Inc. Protalix BioTherapeutics, Inc. JCR Pharmaceuticals Co., Ltd. greenovation Biotech GmbH Neuraltus Pharmaceuticals, Inc. Biosidus S.A. ExSAR Corporation Bioorganic Research and Services S.A. Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/88...rs_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Court Orders Martha Stewart, Emeril Lagasse, Home Shopping Network to Stop Using "SOLINGEN" Certification Mark
Marketwire - Tue Feb 04, 9:17AM CST
Attorneys with Mayback & Hoffman and Devine Goodman, et al. announced that a Tampa federal judge has issued a permanent injunction prohibiting Martha Stewart, Emeril Lagasse, and their respective companies; the Home Shopping Network; and SED International Holdings Inc. from using the "SOLINGEN" certification mark.
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013 Report
M2 - Mon Feb 03, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/f28drr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013" report to their offering. 'Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Scope - A snapshot of the global therapeutic scenario for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - A review of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Athersys, Inc. OPKO Health, Inc. Amicus Therapeutics, Inc. ReGenX Biosciences, LLC ArmaGen Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/f2...saccharido About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium
GlobeNewswire - Thu Jan 30, 3:01PM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that three oral presentations and five posters highlighting its development programs for lysosomal storage diseases will be included at the 10 Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 10-14, 2014 in San Diego, CA.
BioNJ to Honor Patient Advocacy Leaders at Annual Meeting Thursday
Business Wire - Wed Jan 29, 1:12PM CST
BioNJ will honor the first recipients of its Patient Advocate Award tomorrow evening at the BioNJ 21st Annual Dinner Meeting and Networking Event, recognizing outstanding leadership efforts to represent patient interests in the biotechnology and pharmaceutical industries, scientific research and public arenas.
Pompe Disease - Pipeline Review, H2 2013
M2 - Fri Jan 24, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjm87q/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pompe Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pompe Disease. Pompe Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Pompe Disease. - A review of the Pompe Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pompe Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Pompe Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pompe Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and underst Companies Mentioned - Amicus Therapeutics - Audentes Therapeutics - BioMarin Pharmaceutical - EpiVax - Genzyme Corporation - Oxyrane Belgium - Valerion Therapeutics For more information visit http://www.researchandmarkets.com/research/cj...pe_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Amicus Therapeutics Up 9.6%, Shares Break Through Resistance (FOLD)
Comtex SmarTrend(R) - Tue Jan 21, 11:43AM CST
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 9.6% to $2.98 on 1.2x average daily volume. Amicus Therapeutics has traded 395,000 shares thus far today, vs. average volume of 328,000 shares per day. The stock has outperformed the Dow (9.6% to the Dow's -0.6%) and outperformed the S&P 500 (9.6% to the S&P's -0.1%) during today's trading.
Amicus Therapeutics (FOLD) Soars: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:18AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by roughly 11% on the day.
Positive News for Keryx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 3:40PM CST
Positive news flowed in for Keryx Biopharmaceuticals when its Japanese partner, Japan Tobacco Inc. (JT), received manufacturing and marketing approval of Zerenex from the Japanese Ministry of Health, Labour and Welfare.
Amicus Update on Strategy, Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 4:49PM CST
Amicus Therapeutics participated in the 32nd annual J.P. Morgan Healthcare Conference.
Stock to Watch: Amicus Therapeutics Up 8.4% (FOLD)
Comtex SmarTrend(R) - Fri Jan 17, 11:41AM CST
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 8.4% to $2.67 on 2.0x average daily volume. Thus far today, Amicus Therapeutics has traded 653,000 shares, vs. average volume of 329,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's 0.4%) and outperformed the S&P 500 (8.4% to the S&P's -0.0%) during today's trading.
Amicus Therapeutics Provides Full-Year 2014 Strategic Outlook and Financial Guidance
GlobeNewswire - Mon Jan 13, 6:30AM CST
3 Next-Generation Enzyme Replacement Therapies (ERTs) Expected to Enter Clinic in Next 3 Years, Beginning in 2014
